Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
